FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The complaint called the FDA's decision to restrict the compounding of tirzepatide "a reckless and arbitrary decision [...] to deprive patients of a vital treatment for type 2 diabetes and obesity."The U.S. Food and Drug Administration (FDA) is reassessing a decision to ban compounding pharmacies to supply cheaper versions of Eli Lilly And Co's (NYSE:LLY) blockbuster weight loss and diabetes drugs.
美國食品藥品監督管理局（FDA）正在重新評估一項決定，即禁止複方藥房提供更便宜的禮來公司（紐約證券交易所代碼：LLY）重磅減肥和糖尿病藥物。
What Happened: Reuters highlighted how the FDA had banned compounding pharmacies to supply cheaper versions of the medication, but is now reconsidering that decision.
發生了什麼：路透社強調了美國食品藥品管理局是如何禁止複方藥房提供更便宜的藥物的，但現在正在重新考慮這一決定。
The compounding groups Outsourcing Facilities Association and FarmaKeio Custom Compounding had filed a complaint against the FDA for the deciaion but the lawsuit has since been put on hold.
複合組織外包設施協會和Farmakeio定製化合物已就該決定對美國食品藥品管理局提出申訴，但該訴訟此後被擱置。
The complaint called the FDA's decision to restrict the compounding of tirzepatide "a reckless and arbitrary decision [...] to deprive patients of a vital treatment for type 2 diabetes and obesity."
該投訴稱，美國食品藥品管理侷限制複方替西帕肽的決定 「是一個魯莽而武斷的決定 [...]，旨在剝奪患者治療2型糖尿病和肥胖症的重要方法。」
Last week, Eli Lilly said it issued hundreds of cease-and-desist letters to telehealth companies, compounding pharmacies, and medical spas, demanding they halt the production, sale, and promotion of products that imitate its drugs, Mounjaro and Zepbound.
上週，禮來公司表示，它向遠程醫療公司、複合藥房和醫療水療中心發出了數百封停止和終止信，要求他們停止生產、銷售和推廣模仿其藥物的產品Mounjaro和Zepbound。
The tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022.
自2022年以來，名爲Mounjaro和Zepbound的替塞帕肽注射劑一直處於短缺狀態。
Price Action: Lilly stock closed at $931.74 on Friday
價格走勢：禮來股票週五收於931.74美元
- Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names.
- 儘管可能有16種新的肥胖藥物佔據市場主導地位，但諾和諾德、禮來公司仍可能面臨下行壓力：見名字。
